| Literature DB >> 34610962 |
Marieke Burleson1, Janice J Deng2, Tai Qin2, Thu Minh Duong1, Yuqian Yan3, Xiang Gu2, Debodipta Das2, Acarizia Easley2, Michael A Liss4, P Renee Yew1, Roble Bedolla4, Addanki Pratap Kumar4, Tim Hui-Ming Huang1, Yi Zou5, Yidong Chen5, Chun-Liang Chen1, Haojie Huang3, Lu-Zhe Sun6, Thomas G Boyer7.
Abstract
Although the Sonic hedgehog (SHH) signaling pathway has been implicated in promoting malignant phenotypes of prostate cancer, details on how it is activated and exerts its oncogenic role during prostate cancer development and progression is less clear. Here, we show that GLI3, a key SHH pathway effector, is transcriptionally upregulated during androgen deprivation and posttranslationally stabilized in prostate cancer cells by mutation of speckle-type POZ protein (SPOP). GLI3 is a substrate of SPOP-mediated proteasomal degradation in prostate cancer cells and prostate cancer driver mutations in SPOP abrogate GLI3 degradation. Functionally, GLI3 is necessary and sufficient for the growth and migration of androgen receptor (AR)-positive prostate cancer cells, particularly under androgen-depleted conditions. Importantly, we demonstrate that GLI3 physically interacts and functionally cooperates with AR to enrich an AR-dependent gene expression program leading to castration-resistant growth of xenografted prostate tumors. Finally, we identify an AR/GLI3 coregulated gene signature that is highly correlated with castration-resistant metastatic prostate cancer and predictive of disease recurrence. Together, these findings reveal that hyperactivated GLI3 promotes castration-resistant growth of prostate cancer and provide a rationale for therapeutic targeting of GLI3 in patients with castration-resistant prostate cancer (CRPC). IMPLICATIONS: We describe two clinically relevant mechanisms leading to hyperactivated GLI3 signaling and enhanced AR/GLI3 cross-talk, suggesting that GLI3-specific inhibitors might prove effective to block prostate cancer development or delay CRPC. ©2021 American Association for Cancer Research.Entities:
Mesh:
Substances:
Year: 2021 PMID: 34610962 PMCID: PMC9258906 DOI: 10.1158/1541-7786.MCR-21-0108
Source DB: PubMed Journal: Mol Cancer Res ISSN: 1541-7786 Impact factor: 6.333